Targeting Unmet Disease Through Development of Best-in-Class Therapies
We are a clinical-stage biopharmaceutical company focused on building an innovative pipeline of best-in-class drugs to treat liver and gastrointestinal, or GI, diseases. Our most advanced program is focused on the farnesoid X receptor (FXR) an important drug target in multiple liver and GI diseases. We have leveraged our chemistry and biology platform to internally discover a proprietary portfolio of non-bile acid FXR agonists. We purposefully designed MET409, our lead product candidate, to be an optimized, next-generation FXR agonist that we are initially developing as a potentially differentiated and best-in-class treatment for nonalcoholic steatohepatitis (NASH). In addition, we plan to evaluate MET409 as a potential first-in-class treatment for irritable bowel syndrome with diarrhea (IBS-D), and inflammatory bowel diseases (IBD), such as ulcerative colitis and Crohn’s disease. Beyond our FXR program, we are building a pipeline of novel drug candidates against other drug targets by taking advantage of our drug discovery and development capabilities.